~~<i id='3300596E12'><strike id='3300596E12'><tt id='3300596E12'><pre id='3300596E12'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：Wikipedia 2025-08-04 03:39:50 - browse：6

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Novo Nordisk obesity pill bests Wegovy in early trial

leisure time

entertainment

hotspot

entertainment

focus

knowledge

SebastienBozon/AFPviaGettyImagesRochesaidMondayitwasbuyingTelavantHoldingsfor$7.1billionupfront,pick

WSS

J&J lung cancer data amount to new salvo against AstraZeneca

ADCs take center stage as promising cancer treatments

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

First medicine developed to treat MASH expected to be approved soon

J&J lung cancer data amount to new salvo against AstraZeneca

UnitedHealth quietly bought dozens of outpatient centers

hotspot

explore

leisure time

Hollywood unions extend contract negotiations for actors

Health tech investors get more selective as pandemic boom fades

Jerome Adams on the need for new antivirals for Covid

Roche drug slashes death risk in early

Hollywood unions extend contract negotiations for actors

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Anesthesiologist group: stop taking Ozempic before surgery

Change Healthcare cyberattack prompts Medicare loan program

State Dept. review finds Biden bears some blame for Afghanistan failures

RSV shot was 90% effective at preventing hospitalizations in kids

entertainment

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Roche drug slashes death risk in early

IVF, abortion rights issues kick off Biden’s State of the Union

Roche drug slashes death risk in early

The problems with dementia villages

Why a market frenzy over new weight loss drugs defies logic

hotspot

entertainment

focus

knowledge